echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > JCO (IF=51) Liu's team at Southern Medical University found an effective alternative therapy for acute lymphoblastic leukemia

    JCO (IF=51) Liu's team at Southern Medical University found an effective alternative therapy for acute lymphoblastic leukemia

    • Last Update: 2022-09-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    Acute lymphoblastic leukemia (ALL) is the main type of acute leukemia in adults and is a group of diseases


    Currently, in patients with acute lymphoblastic leukemia who received allo-HSCT, there is still controversy


    On September 9, 2022, Liu Qi's team from Southern Hospital of Southern Medical University published online in the journal Journal of Clinical Oncology (IF=51) entitled "Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B.


    Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a treatment for patients with acute lymphoblastic leukemia (ALL


    Overall, the findings suggest that the bucy regimen was not inferior in overall survival, recurrence, disease-free survival, and non-relapse mortality in patients with STANDARD risk B-ALL of CR1 who received allogeneic genes matched with HLA compared with TBI-Cy


    —END—

    The content is [iNature]

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.